Tradipitant
As of the edition of 20 October 2026, Tradipitant is a small molecule: marketed, first approved in 2025 (US); acts on TACR1; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Nereus
- First approved
- 30 December 2025 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Vanda Pharmaceuticals
- Registered trials
- 22, 1 stopped early
- Disease areas
- Skin and connective tissue; Digestive system; Immune system; Inherited and neonatal; Mental health; Chemically induced
US protection
US protection ends in 2030.
The last listed US exclusivity ends in 2030. The application that gives this date is held by Vanda Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Tradipitant.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 10 | 9 | 1 | 0 |
| Phase 3 | 9 | 4 | 4 | 1 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Vanda Pharmaceuticals | Originator and Lead sponsor of trials | 2021 to now |